- Alachkar, Houda , Fulton, Noreen , Sanford, Ben , Malnassy, Greg ... - - Pharmacogenomics J. - 2017
- Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-10102
A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.
There are 140 items
Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P) - based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).
A phase I, open–label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3b follicular lymphoma, or transformed lymphoma (AFT-08)
Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct)